In a letter to the White House Office of Science and Technology Policy (OSTP), SWHR recommended the government prioritize biotechnology […]
SWHR provided recommendations to the Institute for Clinical and Economic Review (ICER) on proposed changes to its 2020 value assessment […]
The U.S. health care system is undergoing transformative changes in the way that it delivers and pays for care. The […]
In a letter to the Secretary of Health and Human Services, SWHR expressed its concerns about the future status of […]
SWHR sent comments to the Food and Drug Administration (FDA) regarding the agency’s new draft guidance on pre- or post-market […]
SWHR provided comments to the Food and Drug Administration (FDA) on its recently released draft guidance pertaining pregnancy safety study […]
SWHR provided input to the Institute for Clinical and Economic Review (ICER) on the 2020 update to its value assessment […]
SWHR sent letters to the Senate and House subcommittees that oversee funding for the National Institutes of Health (NIH) urging […]
SWHR sent comments to the U.S. Department of Health and Human Services (HHS) in response to the Pain Management Best […]
SWHR developed a set of principles to address diversity within the Patient-Focused Drug Development (PFDD) Program. The PFDD Program, housed […]